Browsing Cancer Therapeutics by author "Porta, Nuria"
Now showing items 1-9 of 9
-
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky, MP; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; et al. (ELSEVIER, 2020-02-21)BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence ... -
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira, S; Porta, N; Arce-Gallego, S; Seed, G; Llop-Guevara, A; et al. (AMER ASSOC CANCER RESEARCH, 2021-11-01)PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed ... -
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno, P; Gurel, B; Pereira, R; Crespo, M; Rekowski, J; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-28)PURPOSE: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ... -
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-04-01)The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ... -
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo, J; Porta, N; Bianchini, D; McGovern, U; Elliott, T; et al. (ELSEVIER SCIENCE INC, 2020-01-01)BACKGROUND: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and ... -
Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou, C; Porta, N; Sharma, B; Levine, D; Koh, D-M; et al. (RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2021-09-01)Purpose To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, ... -
TOPARP-B: A Randomised Phase 2 Trial Evaluating Two Doses of Olaparib Against Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
Hall, E; De Bono, J; Porta, N; Miranda, S; Flohr, P; et al.